Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Zasocitinib · NDI-034858, TAK-279

Small molecule · developed by TAKEDA PHARMACEUTICAL CO

Phase 3 Most advanced trial

TAK Developer

2 Registered trials

What is Zasocitinib?

Zasocitinib is an investigational small-molecule drug studied in Crohn's Disease, Psoriatic Arthritis.

At a glance

Also known as: NDI-034858, TAK-279, TAK- 279
Drug type: Small molecule
Therapy area: Gastroenterology
Developer: TAKEDA PHARMACEUTICAL CO (TAK)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: C293MNS6TQ

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07286058	Phase 3	Psoriatic Arthritis	Recruiting	TAK
NCT06233461	Phase 2	Crohn's Disease	Recruiting	TAK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Crohn's DiseasePsoriatic Arthritis

More from TAKEDA PHARMACEUTICAL CO

Maribavir FDA approved Susoctocog Alfa FDA approved Vedolizumab FDA approved Vonicog Alfa FDA approved Elritercept Phase 3 GDX012 Phase 1/2 IGI Phase 3 Mezagitamab Phase 3 MNI-792 Phase 1 Pevonedistat Phase 2/3 Soticlestat Phase 3 TAK-186 Phase 1/2

Follow TAK, the company behind Zasocitinib

See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TAK catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z